News Related to Thyroid Eye Disease

Related coverage linked through entity extraction aliases.

FcRn Inhibitors and Emerging Therapies Reshape Myasthenia Gravis Treatment Landscape

Apr 29, 2026

Three FcRn inhibitors are approved for generalized myasthenia gravis, with a head-to-head trial of efgartigimod and nipocalimab underway. Emerging therapies including telitacicept, gefurulimab, and CAR-T cell therapy (KYV-101) show promise, while Immunovant's batoclimab failed TED trials.

Viridian Reports Positive Phase 3 Results for Elegrobart in Thyroid Eye Disease

Mar 31, 2026

Viridian Therapeutics reported positive Phase 3 results for elegrobart in thyroid eye disease, showing significant proptosis reduction and diplopia resolution. The company plans a BLA submission in Q1 2027 and has another IGF-1R inhibitor, veligrotug, under FDA Priority Review with a June 2026 decision date.